Sphan et al. studied 712 PC patients with prostate-specific antigen (PSA) > 20 ng/mL and found that a combination of additional risk factors (e.g., Gleason score (GS) 8–10, clinical stage (c) T3–4) at presentation were associated with unfavorable histopathology and worse cancer-specific outcomes [16]. This evidence concerns the gene KLK3 and cancer.